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Immunization with a Dominant-Negative
Recombinant HSV Type 1 Protects against
HSV-1 Skin Disease in Guinea Pigs
Richard Brans1, Elof Eriksson1 and Feng Yao1
CJ9-gD belongs to a new class of replication-defective recombinant herpes simplex viruses (HSVs) type 1 that
can function in trans to prevent the replication of wild-type HSV in co-infected cells. Furthermore, CJ9-gD
cannot establish latent infection in vivo and it expresses high levels of the major HSV-1 antigen glycoprotein D
immediately following infection. In this study we show that guinea pigs immunized with CJ9-gD developed at
least 9,600-fold higher titers of HSV-1-specific neutralization antibodies than mock-immunized controls. After
challenge with wild-type HSV-1, all 10 mock-immunized guinea pigs developed multiple skin lesions with an
average of 53.3 lesions per animal, whereas only 2 minor lesions were found in 1 of 10 CJ9-gD-immunized
animals, representing a 267-fold reduction on the incidence of primary herpetic skin lesions in immunized
animals. Quantitative PCR analysis revealed that the amount and frequency of wild-type HSV-1 viral DNA
present in dorsal root ganglia of immunized animals was significantly lower than that in mock-immunized
controls. Collectively, we demonstrate that vaccination with CJ9-gD elicits strong and protective immune
responses against primary HSV-1 skin disease and reduces the extent of latent infection by challenge virus.
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INTRODUCTION
Infection with herpes simplex virus (HSV) type 1 is still a
major health issue, as up to 60–90% of people worldwide are
seropositive (Whitley and Roizman, 2001; Cowan et al.,
2003; Pebody et al., 2004; Cunningham et al., 2006; Xu
et al., 2006). Primary infection is followed by establishment
of latency in sensory neurons, giving rise to recurrent disease
and viral shedding. HSV-1 mainly causes orofacial infections,
with 20–40% of the general population experiencing
recurrent labial or perioral lesions (Embil et al., 1975).
Although outbreaks are usually mild, in immunocompro-
mised individuals, lesions can be more severe and may
spread to cause major morbidity (Stanberry et al., 2000).
Other cutaneous diseases caused by or associated with
HSV-1 include herpetic whitlow, herpes gladiatorum, eczema
herpeticum, and erythema multiforme (Hwang and Spruance,
1999). Herpetic keratitis and herpes encephalitis are infre-
quent but potentially grave complications of orofacial HSV-1
infections (Liesegang, 1991; Whitley, 2006). Moreover, recent
reports indicate that, in developed countries, HSV-1 has
become the main causative agent for primary genital herpes in
adolescents, young women, and homosexual men (Lafferty
et al., 2000; Lowhagen et al., 2000; Roberts et al., 2003; Jin
et al., 2006).
There is no effective medication to prevent primary
infection, no cure for latent infection, and only limited
possibilities for treatment and prevention of recurrences
(Whitley and Roizman, 2001; Spruance and Kriesel, 2002).
Different vaccine strategies have been developed mainly
against HSV-2, including peptides, proteins, killed virus,
delivering HSV antigens by plasmid DNA and heterologous
viral vectors, as well as replication-defective viruses and
attenuated replication-competent viruses (Bernstein and
Stanberry, 1999; Koelle and Corey, 2003). Subunit vaccines
consisting of glycoproteins and an adjuvant appeared to be
safe and effective against HSV in several animal models
(Stanberry et al., 1987; Ghiasi et al., 1996; Bourne et al.,
2005), but showed no or only limited benefit against genital
HSV-2 disease in phase III clinical trials (Corey et al., 1999;
Stanberry et al., 2002). A live virus vaccine elicits broader
and longer-lasting immune responses (Wachsman et al.,
2001; Prichard et al., 2005). However, the use of replication-
competent viruses raises safety concerns, including the risk of
establishing latency and causing morbidity especially in
immunocompromised individuals (Meignier et al., 1988,
1990). Replication-defective HSVs lack functions essential
for viral replication or assembly of progeny virus particles
(Dudek and Knipe, 2006), but elicit protective immune
responses in mice and guinea pigs (Nguyen et al., 1992;
Boursnell et al., 1997; Brehm et al., 1999; Da Costa et al., 1999).
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Nevertheless, replication-defective viruses might regain
replication competence in the presence of wild-type virus
or induce reactivation of wild-type virus from latent infection.
Thus, their use as a vaccine, particularly in latently infected
individuals, imposes certain risks.
Using the T-REx (Invitrogen, Carlsbad, CA) tetracycline
gene switch technology developed in this laboratory, and the
dominant-negative mutant polypeptide, UL9-C5353C, of
HSV-1 origin binding protein UL9, we previously generated
an UL9-C535C-expressing HSV-1-recombinant CJ83193,
capable of blocking its own replication as well as that of
wild-type HSV-1 and HSV-2 in co-infected cells (Yao and
Eriksson, 1999, 2002). In a mouse ocular model, we demons-
trated that CJ83193 is an effective vaccine against wild-type
HSV-1 (Augustinova et al., 2004). To further ensure its safety
and augment its efficacy as a vaccine against HSV infection,
we recently developed a CJ83193-derived HSV-1-recombi-
nant CJ9-gD, which contains an additional deletion in the
essential UL9 gene and an extra copy of the gene encoding
the major HSV-1 antigen glycoprotein D (gD) under the
control of the tetO-bearing hCMV immediate-early promoter.
It is documented that CJ9-gD is completely replication
defective, expresses much higher levels of gD than CJ83193
in infected cells, and is significantly more effective than
CJ83193 in inducing HSV-1-specific neutralizing antibodies
in mice (Lu et al., unpublished data). The ability of CJ9-gD to
elicit strong and long-lasting HSV-1 T-cell response has also
been illustrated in mice (Brans and Yao, unpublished data).
The guinea pig model of HSV-1 skin infection was
established in 1974 by Hubler et al., and since then has
been widely used to test various antiviral substances as local
treatment against HSV infection (Hubler et al., 1974; Schafer
et al., 1977; Alenius and Oberg, 1978; Spruance et al., 1986;
Spruance and McKeough, 1988; McKeough and Spruance,
2001). The advantage of the guinea pig model is that the HSV
lesions resemble those seen in humans, including develop-
ment of latency. To our knowledge, this is the first report of
using the guinea pig model of skin infection to test the
efficacy of a prophylactic vaccine against HSV-1 infection.
We demonstrate that immunization with CJ9-gD elicits strong
protective immune responses against primary herpes skin
disease and reduces frequency and magnitude of latent
infection.
RESULTS
Induction of HSV-1-specific IgG and neutralization antibody
titers
The average HSV-1-specific IgG antibody titer for guinea pigs
immunized with CJ9-gD at a dose of 2 107 PFU increased
significantly from the second to the third vaccination with a
peak value of 6,667 (Pp0.05). The titer did not increase
significantly after challenge with wild-type HSV-1 (P¼ 0.3).
No HSV-1-specific antibody was detectable by ELISA in a
dilution 1:100 of serum from mock-immunized controls
(Figure 1a).
The HSV-1-specific neutralization antibody titer was
detected in serum from all immunized animals and increased
significantly from the second to the third vaccination
(Po0.05) with a peak titer 2 weeks after the third vaccination
of 19,200. No HSV-1-specific neutralization antibody was
detected in serum from mock-immunized animals at 1:2
dilution before challenge. After challenge, the neutralization
antibody titer in immunized animals was 2.6-fold higher than
that in mock-immunized controls (Po0.005; Figure 1b).
To investigate further the effectiveness of CJ9-gD, the
immunization dose was reduced to 5 106 PFU per animal,
resulting in a neutralization antibody titer of 8,267, which
was not significantly lower than those found after immuniza-
tion with 2 107 PFU (P¼0.5). Again, the neutrali-
zation antibody titer increased after the third immunization
(Figure 1b).
Protection from herpetic skin disease
The development and clinical appearance of lesions caused
by challenge virus in mock-vaccinated guinea pigs was
consistent with the previous observations (Hubler et al.,
1974; Alenius and Oberg, 1978). On day 1 after chal-
lenge, minor skin irritation due to the viral inoculation was
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Figure 1. Induction of herpes simplex virus (HSV) type 1-specific IgG
and neutralization antibodies. Hartley guinea pigs (two sets of six and one
set of eight) were either mock-immunized with DMEM or immunized with
CJ9-gD by subcutaneous injection at a dose of 2107 PFU (n¼ 6) or 5 106
PFU (n¼ 4) per animal. On days 14 and 28 after primary immunization,
guinea pigs were boosted. Serum was obtained from all animals 14 days after
each immunization and 28 days after the challenge. (a) Unprocessed serum
was tested for HSV-1-specific total IgG by ELISA and (b) heat-inactivated
serum was used for HSV-1-specific neutralization antibody assays. The
indicated values represent the mean levels±SD. P-values were assessed
by Student’s t-test (*Pp0.05, **Po0.05, ***Po0.005, ****Po0.0005).
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observed. Beginning from day 2, small grouped vesicles on
an erythematous base appeared, which enlarged and started
to coalesce between day 3 and 5. From day 6, lesions started
to dry out, and crusts built up, which subsequently fell off
over the following days. By day 14 after inoculation, skin
areas were healed (Figures 2c and 3). No animal developed
zosteriform lesions or showed signs of neurological disease.
The impact of immunization with CJ9-gD on the incidence
of skin lesions is summarized in Table 1. All 10 mock-
immunized guinea pigs developed herpetic skin lesions in all
40 tested areas (100%) following challenge with wild-type
HSV-1. In contrast, only one of 24 challenged areas in six
animals immunized with 2 107 PFU of CJ9-gD exhibited
two herpetiform lesions, resulting in an average of 0.3 lesions
per immunized animal. In the corresponding control group,
an average of 35.8 lesions per mock-vaccinated animal was
detected on day 4 postchallenge (Po0.001) (Figure 2a). All
four guinea pigs immunized with 5 106 PFU of CJ9-gD
were completely protected from primary skin disease
and showed no lesions in any area, whereas the correspond-
ing mock-immunized controls showed an average of
79.5 lesions per animal on day 4 postchallenge (Pp0.001)
(Figure 2b). Taken together, the average number of lesions
per mock-immunized animal on day 4 postchallenge was
53.3. Thus, the overall incidence of primary herpetic skin
lesions in immunized animals was 267-fold reduced com-
pared with mock-immunized controls (Po0.001). Moreover,
it should be noted that the two lesions found in the above-
mentioned immunized guinea pig were less pronounced and
healed 2–3 days earlier than the lesions in mock-immunized
control animals (Figure 3).
Reduction of viral titer in skin swabs
As demonstrated in Figure 4, the average virus titer per lesion
of skin swabs from mock-vaccinated guinea pigs (n¼45
lesions) on day 4 after challenge was 14-fold higher than the
titer recovered from a skin swab on the two lesions found
in one animal immunized with 2107 PFU of CJ9-gD
(CJ9-gD L), representing a 93% reduction of the virus titer.
No virus was recovered in skin swabs from three test areas
of guinea pigs immunized with 2107 PFU of CJ9-gD
without visible lesions.
Protection from latent viral infection
Thirty-four thoracic and lumbar dorsal root ganglia per
guinea pig were harvested from three animals immunized
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Figure 2. Prevention of herpes simplex virus (HSV) skin lesions in immunized animals. Six weeks after the initial immunization, each flank of Hartley
guinea pigs described in the legend of Figure 1 was divided into two 4 cm2 squares and each individual square was infected twice with 40 ml of wild-type HSV-1
strain McKrae at a total dose of 8.8 104 PFU using a microseeding machine. After challenge, the animals were monitored daily for clinical symptoms.
The average number of lesions per animal immunized with a dose of (a) 2107 PFU or (b) 5106 PFU of CJ9-gD were compared with those found in
mock-immunized guinea pigs. The indicated values represent the mean number of lesions±SD on day 4 postchallenge. P-values were assessed by Student’s
t-test (*Po0.001, **Pp0.001). Panel (c) shows a representative test square in a mock-vaccinated guinea pig (upper panel) and a CJ9-gD-vaccinated guinea
pig at a dose of 2 107 PFU (lower panel) following challenge with the wild-type HSV-1 on days 3, 6, 10, and 14.
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with 5106 PFU of CJ9-gD and four mock-immunized
controls. The whole DNA was extracted and tested for latent
viral DNA using quantitative real-time PCR. The limit of
detection was five DNA copies per reaction (correlation
coefficient±SD: 0.96±0.029). In mock-vaccinated controls,
a significantly higher number of dorsal root ganglia per
animal carried latent HSV DNA than in immunized animals
(65.93 vs 20.91%, Pp0.005, Figure 5a). Similarly, the
average amount of latent HSV DNA per dorsal root ganglion
was significantly higher in mock-vaccinated controls than in
immunized animals (775 DNA copies vs 272 DNA copies,
Pp0.05, Figure 5b).
DISCUSSION
Using the guinea pig model of HSV-1 skin infection described
by Hubler et al. (1974), Spruance et al. (1986) demonstrated
that 3% foscarnet cream and 5% acyclovir cream applied
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Figure 3. Reduction of severity and duration of herpes simplex virus (HSV)
skin lesions. After challenge with wild-type HSV-1, the development
(as indicated by solid line) and healing (as indicated by dashed line) of lesions
were scored: erythema and slight edema (0.5), erythema and one or two small
vesicles (1), erythema and numerous small vesicles (2), numerous large
vesicles and coalesced vesicles (3), vesicles dried, large crusts (III), crusts
fallen off to 50% (II), about 10% of crusts remaining (I), uninfected or healed
area, no crusts or vesicles. Trauma from the inoculation or traces from
the infection can be present (0). The score of the two herpetiforme lesions
found in only one Hartley guinea pig immunized with 2 107 PFU of
CJ9-gD was compared for each day, with the average score of lesions in
mock-immunized animals.
Table 1. Prevention of herpetic skin lesions in
immunized animals1
Test squares with HSV lesions
Mock CJ9-gD (2107 PFU) CJ9-gD (5106 PFU)
Exp. 1 (n=3) 12/12 0/12
Exp. 2 (n=3) 12/12 1/12
Exp. 3 (n=4) 16/16 0/16
1Six weeks after the initial immunization, each flank of Hartley
guinea pigs, as described in the legend of Figure 1, was divided
into two 4 cm2 squares. Each individual square was infected twice
with 40 ml of wild-type HSV-1 strain McKrae at a total dose of 8.8 104
PFU using a microseeding machine. After challenge, the animals
were monitored daily and the number of squares with herpes lesions
were counted.
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Figure 4. Reduction of viral titer in skin swabs. After challenge, two
herpetiforme lesions appeared in one test square in one guinea pig
immunized three times with 2107 PFU of CJ9-gD (CJ9-gD L). On day 4
postchallenge, these two lesions and 45 lesions randomly selected from
mock-immunized animals were opened up with a needle, swabbed with a
moist calcium alginate swab, and assayed for infectious virus by standard
plaque assay on Vero cell monolayers. The indicated values represent the
mean virus titer per lesion±SE. No infectious virus was detected in skin
swabs taken from three test areas of CJ9-gD-immunized guinea pigs that
showed no visible skin lesions.
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Figure 5. Protection from latent viral infection. Thirty-five days after
challenge, 34 thoracic and lumbar dorsal root ganglia (DRG) per guinea pig
were harvested from three animals immunized with 5 106 PFU of CJ9-gD
and four mock-immunized animals. The whole DNA was extracted and tested
for latent viral DNA using quantitative real-time PCR. The percentage of
(a) latently infected DRG per guinea pig and (b) the latent viral DNA per
DRG were determined. The results are indicated as mean values±SEs.
P-values were assessed by Student’s t-test (*Pp0.005, **Pp0.05).
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once per day for 3 days starting 24 hours after inoculation of
2105 PFU of wild-type HSV-1 per test area could not
prevent the appearance of lesions and led only to a reduced
mean number of lesions of 54 and 19%, respectively.
Similarly, oral administration of acyclovir in drinking water
at 5mgml1 beginning 24 hours after infection with HSV-1
had no impact on the number of lesions (Spruance and
McKeough, 1988). The efficacy of topical acyclovir clearly
depends on an early initiation of therapy after viral
inoculation (Park et al., 1980), which is in accordance with
findings that the maximal virus replication in the guinea
pig skin is reached within 24 hours after inoculation (Schafer
et al., 1977). Thus, the preexisting immunity induced by an
effective prophylactic HSV vaccine might be more capable of
limiting viral replication at an early stage of infection and
subsequently be more efficient in preventing skin disease.
As major HSV antigen, gD has been the main target for
HSV subunit vaccine development (Stanberry et al., 2000;
Whitley and Roizman, 2002; Koelle and Corey, 2003) and
other vaccine strategies, including gD-expressing recombi-
nant vaccinia virus, adenovirus, and varicella zoster virus
(Zheng et al., 1993; Heineman et al., 1995; Bernstein, 2000).
In a recent phase III clinical trial, a subunit vaccine based on
HSV-2 gD exhibited an effectiveness of 75% in protection
from clinically apparent genital herpes in HSV-seronegative
women (Corey et al., 1999). A study by Hoshino et al. (2005)
demonstrates that the replication-defective HSV-2-recombi-
nant dl5-29 is more effective than an HSV-2-gD-based
subunit vaccine in inducing protective immune responses
against HSV-2 genital herpes in mice and guinea pigs.
Because both CJ9-gD and dl5-29 defect at viral DNA
replication, it is reasonable to believe that the replication-
defective HSV-1 recombinant CJ9-gD would be superior to
an HSV-1-gD-based subunit vaccine in prevention of HSV-1
infection, in particular, considering that CJ9-gD expresses
high levels of gD, induces the same level of anti-HSV-1-
specific neutralization antibodies as wild-type HSV-1 in
mice, and is capable of eliciting long-term HSV-1 antibody
and T-cell responses (Brans and Yao, unpublished data).
In this report, we investigated the efficacy of CJ9-gD as a
prophylactic vaccine against HSV-1 skin infection in guinea
pigs. We modified the model of Hubler et al. by using a
microseeding machine (Eriksson et al., 1998) for viral inocu-
lation instead of a spring-loaded vaccination instrument. The
oscillating needles of the microseeding machine provide
an even introduction of virus into the skin at a controlled
depth, covering the whole surface of a demarcated area.
We demonstrate that immunization with 2107 PFU or
5106 PFU of CJ9-gD elicits strong immune responses in
guinea pigs, indicated by high titers of HSV-1-specific
antibodies. Titers increased significantly from the second to
the third vaccination with 2107 PFU of CJ9-gD (Pp0.05),
suggesting that three vaccinations might provide a better level
of protection. Notably, neutralization antibody titers in immu-
nized animals were significantly higher than those induced
by challenge virus in mock-immunized controls (Po0.0005),
indicating that immunization with CJ9-gD generates a
greater HSV-1-specific humoral immune response than single
infection with wild-type HSV-1 at a dose of 3.5 105
PFU, microseeded into a skin area of 16 cm2 per animal.
Cellular immune response was not tested in this study due
to the lack of sufficient immunological reagents specific for
guinea pigs. We do, however, demonstrate that immuniza-
tion with CJ9-gD in mice elicits strong HSV-specific Th1-like
immune response as indicated by high expression of IFN-g
and IL-2 and low expression of IL-4 by lymphocytes isolated
from immunized mice upon stimulation with UV-inactivated
HSV-1 (Brans and Yao, unpublished data).
Apart from one guinea pig that showed two mild and
fast healing lesions in only one area, all animals immunized
with 2 107 PFU of CJ9-gD exhibited no signs of herpetic
skin disease after challenge with wild-type HSV-1 as well as
all animals immunized with 5 106 PFU of CJ9-gD. This was
in strong contrast to mock-vaccinated guinea pigs, which
developed an average of 53.3 lesions per animal. Thus,
the frequency of lesions was significantly reduced (Po0.001),
as well as their severity and duration, indicating that
immunization with CJ9-gD can effectively protect guinea
pigs from clinical disease and ameliorate symptoms. This is
most likely due to a reduced replication of challenge virus
after skin infection, as viral titers of swabs taken from the two
lesions in vaccinated animals were reduced by 93% in
comparison with titers seen in mock-vaccinated animals and
as no infectious virus was detected in challenged areas that
exhibited no sign of herpetic lesion.
Neither in the mock-vaccinated animals nor in the vacci-
nated animals did spontaneous recurrences appear during the
4 weeks of observation after challenge with wild-type HSV-1.
Real-time PCR results indicate that immunization with
5106 PFU of CJ9-gD did not completely prevent latent
infection of dorsal root ganglia. However, immunization with
CJ9-gD significantly reduced the number of latently infected
ganglia per animal (Po0.006) and the total amount of latent
viral DNA per ganglion (Pp0.05). As the quantity of latent
viral DNA strongly correlates with the risk of reactivation
(Lekstrom-Himes et al., 1998; Sawtell, 1998), immunization
with CJ9-gD could potentially minimize the risk of recurrent
disease or asymptomatic viral shedding. Apparently, guinea
pigs carrying lower amounts of latent virus after genital
challenge with HSV-2 have a lower incidence and frequency
of recurrent disease (Bourne et al., 2005). This is in accor-
dance with unpublished data from our group, which shows
that immunization of guinea pigs with CJ9-gD significantly
reduces the amount of latent virus in dorsal root ganglia after
genital challenge with wild-type HSV-2 compared with
mock-immunized controls and completely protects immu-
nized animals from recurrent genital herpes (Brans and Yao,
unpublished data).
It should be noted that the microseeding technique used
in this study is an invasive inoculation method, although
the size of each inoculated test area was quite extensive, in
particular, given that each 4 cm2 area was challenged with
8.8104 PFU of wild-type HSV-1. Under these conditions, it
is presumably more difficult to confine the establishment of
acute and latent infection than after a typical orofacial skin
infection in humans. Given the severity and number of skin
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lesions seen in all mock-vaccinated controls and the very
limited disease in vaccinated animals, it is reasonable to
expect that vaccination with CJ9-gD would likely provide a
complete protection against skin lesions should a lower
dose of challenge virus be used. Moreover, as seen with
other vaccine candidates, prophylactic vaccination against
HSV most likely is not capable of creating sterilizing
immunity to eliminate primary infection; a more realistic
goal for a vaccine would be to protect the host from
symptomatic primary disease and to reduce latency (Bern-
stein and Stanberry, 1999; Stanberry et al., 2000; Wachsman
et al., 2001; Whitley and Roizman, 2002; Koelle and Corey,
2003; Bourne et al., 2005).
In conclusion, this study demonstrates that immunization
with CJ9-gD effectively protects guinea pigs from primary
HSV-1 skin disease and significantly reduces the frequency
and magnitude of latent infection.
MATERIALS AND METHODS
Animals
Female Hartley guinea pigs (300–350 g) were obtained from Charles
River Breeding Laboratories (Wilmington, MA) and housed under
conditions approved by Harvard Medical Area Standing Committee
on Animals.
Cells and viruses
African Green Monkey Kidney (Vero) cells and RUL9-8 cells, a cell
line derived from U2OS cells expressing UL9 and the tetracycline
repressor (tetR), were grown and maintained in DMEM growth
medium as described previously (Yao et al., 2006).
Wild-type HSV-1 McKrae strain (a kind gift of Dr Priscilla A
Schaffer, Harvard Medical School) was propagated and plaque-
assayed on Vero cells. CJ9-gD was derived from CJ83193 by
replacing the essential UL9 gene with the HSV-1 gD gene driven
by the tetO-containing hCMV major immediate-early promoter
(Lu et al., unpublished data). CJ83193 is a replication-defective
virus, which encodes the dominant-negative HSV-1 polypeptide
UL9-C535C under control of the tetO-bearing hCMV major
immediate-early promoter (Yao and Eriksson, 1999). CJ9-gD was
propagated and plaque-assayed in RUL9-8 cells.
Immunization and challenge
Two sets of six guinea pigs each and one set of eight guinea pigs
were randomly assigned to two groups. Animals were either mock-
immunized with DMEM or immunized with CJ9-gD by subcuta-
neous injection of 50 ml in the right and left hind limb at a dose of
2 107 PFU (n¼ 6) or 5 106 PFU (n¼ 4) per guinea pig. On day 14
and 28 after primary immunization, animals were boosted. At day 14
after each immunization and one day before viral challenge, serum
was obtained from saphenous veins and stored at 801C. Six weeks
after the initial immunization, the hair on both flanks of all animals
was removed with an electrical clipper and depilated with Nair
Cream (Church & Dwight Co. Inc., Princeton, NJ). The hairless area
on each flank was divided into two 4 cm2 squares. Each square was
infected twice with 40ml of wild-type HSV-1 strain McKrae at a total
dose of 8.8 104 PFU using a microseeding machine consisting of a
group of six solid oscillating needles (Eriksson et al., 1998). The
device was run twice over each test square in a steady and
continuous motion, covering the whole surface and introducing
perforations into the skin at a depth of 1mm.
Clinical observations
After challenge with wild-type HSV-1 strain McKrae, the animals
were monitored daily. The number of lesions were counted and the
progress of disease was scored as described before (Alenius and
Oberg, 1978): erythema and slight edema (0.5), erythema and one or
two small vesicles (1), erythema and numerous small vesicles (2),
numerous large vesicles and coalesced vesicles (3), vesicles dried,
large crusts (III), crusts fallen off to 50% (II), about 10% of crusts
remaining (I), uninfected or healed area, no crusts or vesicles; trauma
from the inoculation or traces from the infection may be present (0).
Skin swab and plaque assay
On day 4 postchallenge, lesions in one area per guinea pig were
opened up with a 27G needle, swabbed with a moist calcium
alginate swab (Fisher Scientific, Suwanee, GA), which was kept in
1ml of DMEM and stored at 801C until assayed for infectious virus
by standard plaque assay on Vero cell monolayers.
Detection of HSV-1-specific neutralization antibody titers
Blood was obtained from the saphenous veins and neutralization
antibody titers were determined in the presence of complement as
described previously (Augustinova et al., 2004).
ELISA for HSV-1-specific IgG
Enzyme-linked immunosorbent assays were carried out in 96-well
microtiter plates (Corning Costar 9018). Plates were coated at 41C
overnight with either 120 ngwell1 of HSV-1-infected Vero cell
extract or uninfected Vero cell extract (Advanced Biotechnologies
Incorporated, Columbia, MD) in a final volume of 100 ml of
carbonate bicarbonate buffer. Wells were then blocked with 5%
milk in PBS for 2 hours at 371C. Plates were washed once with 2.5%
milk in PBS. Serial twofold dilutions of serum samples (starting at
1:250) were prepared in growth medium and applied to the coated
plates. After 1.5 hours of incubation at 371C, plates were washed
four times with PBS containing 2.5% milk and 0.05% TW-20,
followed by the addition of HRP-conjugated rabbit anti-guinea pig
IgG (Abcam Inc., Cambridge, MA) at a 3,000-fold dilution in PBS
containing 5% milk. Plates were incubated for 1 hour at 371C,
washed five times with wash buffer and once with PBS, followed
by peroxidase assay (Bio-Rad, Hercules, CA) according to the
manufacturer’s recommendations. The HSV-1-specific IgG titer was
defined as the final twofold dilution yielding an OD450 reading
greater than 0.2U above the OD value of wells coated with
uninfected Vero cell extract.
Quantitative real-time PCR
Thirty-four thoracic and lumbar dorsal root ganglia per guinea pig
were collected 35 days after skin infection with wild-type HSV-1
from three animals immunized with 5 106 PFU of CJ9gD and four
mock-vaccinated animals to determine the magnitude of latent
infection. Each ganglion was kept separately in 0.5ml of normal
growth medium and stored at 801C for further processing. Using
the DNeasy tissue kit (Qiagen, Santa Clarita, CA), genomic DNA was
isolated from each dorsal root ganglion, suspended in 60 ml AE
buffer, and stored at 801C. For real-time PCR, we applied a method
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described by Aldea et al. (2002) introducing minor modifications.
The reaction was performed in a Gene Amp 5700 Sequence
Detection System (PE Biosystems, Foster City, CA) using a reaction
volume of 50 ml containing 10 ml DNA (10 ng), 1 ABsolute QPCR
SYBR Green ROX Mix (Abgene, Rochester, NY), and 0.4 mM
concentrations of primers (Invitrogen, Carlsbad, CA) specific for
the HSV DNA polymerase coding region (forward: 50 GCT CGA
GTG CGA AAA AAC GTT C; reverse: 50 CGG GGC GCT CGG CTA
AC). The real-time PCR conditions were as follows: 951C for
15minutes, followed by 50 cycles of 951C for 30 seconds, 621C for
10 seconds, and 721C for 12 seconds. For melting curve analysis,
temperature was held for 15 seconds at 951C and 20 seconds at
601C, followed by a 20minute slow ramp from 60 to 951C.
The HSV-1 DNA polymerase (UL30) encoding plasmid pNN3
used for the standard curve in real-time PCR reaction was the kind
gift of Priscilla A Schaffer (Harvard Medical School). The 215 bp
PCR-amplified UL-30 fragments were confirmed by agarose gel
analysis.
Statistical analysis
For statistical analysis Student’s t-tests were performed.
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